Prospects of HIV Env modification as an approach to HIV vaccine design

Current HIV Research

Volumn 5, Issue 6, 2007, Pages 507-513

  Hu, Shiu Lok ^a   Stamatatos, Leonidas ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Env modifications; HIV Env; HIV vaccines; Neutralizing antibodies

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ANTIGENICITY; DEGLYCOSYLATION; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; EPITOPE MAPPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; MOLECULAR INTERACTION; NONHUMAN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN TARGETING; REVIEW; VACCINE PRODUCTION; VIRUS DETECTION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIGEN-ANTIBODY REACTIONS; EPITOPE MAPPING; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HUMANS; PEPTIDE FRAGMENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38949170716     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207782418542     Document Type: Review

References (83)

1. Back NK, Smit T, De L, Jong JJ, Keulen W, Schutten M, Goudsmit J, Tersmette M. (1994). An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virtis neutralization. Virology. 199:431-438.
2. Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP. (2006). A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology. 360:329-340
3. Beddows S, Schulke N, Kirschner M, Barnes Y, Franti M, Michael E, Ketas T, Sanders RW, Maddon PJ, Olson WC, Moore JP. (2005). Evaluating the immunogemicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. Journal of Virology. 79:8812-27.
4. Benjouad A, Gluckman JC, Rochat H, Montagnier L, Bahraoui E. (1992). Influence of carbohydrate moieties on the inummogenicity of human immunodeficiency virus type 1 recombinant gp160. Journal of Virology. 66:2473-83.
5. Bernstein HB, Tucker SP, Hunter E, Schutzbach JS, Compans RW. (1994). Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. Journal of Virology. 68:463-8.
6. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, Guo Y, Kajumo F, Anselma DJ, Maddon PJ, Olson WC, Moore JP. (2000). A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. Journal of Virology. 74:627-43.
7. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey.C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. (2004). Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. Journal of Virology. 78:13232-52.
8. Bolmstedt A, Hinkula J, Rowcliffe E, Billet M, Wahren B, Olofsson S. (2001). Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan. Vaccine. 20:397-405.
9. Bolmstedt A, Sjolander S, Hansen JE, Akerblom L, Hemming A, Hu SL, Morein B, Olofsson S. (1996). Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology. 12:213-20.
10. Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, Autran B, Barin F. (2006). Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS. 20:1923-1930.
11. Burke B, Derby NR, Kraft Z, Saunders CJ, Dai C, Llewellyn N, Zharkikh I, Vojtech L, Zhu T, Srivastava IK, Barnett SW, Stamatatos L. (2006). Viral evolution in macaques coinfected with CCR5-and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies. Virology. 355:138-51.
12. Cao J, Sullivan N, Deajardin E, Parolin C, Robinson J, Wyatt R, Sodroski J. (1997). Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. Journal of Virology. 71:9808-9812.
13. Cheng-Mayer, C, Brown A, Harouse J, Luciw PA, Mayer AJ. (1999). Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. Journal of Virology. 73:5294-300.
14. Clevestig P, Pramanik L, Leitner T, Ehrnst A. (2006). CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. Journal of Genetic Virology. 87:607-12.
15. Coffin JM. (1986). Genetic Variation in AIDS Viruses Cell 46:14.
16. Cole KS, Steckbeck JD, Rowles JL, Desrosiers RC, Montelaro RC. (2004). Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. Journal of Virology. 78:1525-39.
17. Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, Binley JK Stamatatos L. (2006). Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Journal of Virology. 80:8745-62.
18. Earl PL, Broder CC, Doms RW, Moss B. (1997). Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. Journal of Virology. 71:2674-2684.
19. Earl PL, Sugiura W, Montefiori DC, Broder CC, Lee SA, Wild C; Lifson J, Moss B. (2001). Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. Journal of Virology. 75:645-53.
20. Gao F, Weaver EA, Lu Z, Li Y, Liao HX, Ma B, Alam SM, Scearce RM, Sutherland LL, Yu JS, Decker JM, Shaw GM, Montefiori DC, Korber BT, Hahn BH, Haynes BF. (2005). Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group in consensus envelope glycoprotein. Journal of Virology. 79:1154-63.
21. Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, de Jong JJ, Goudsmit K, Nara PL. (1997). Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. Journal of Immunology 159:279-89.
22. Geyer H, Holschbach C, Hunsmann G, Schneider J. (1988). Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. Journal of Biological Chemistry. 263:11760-7.
23. Grundner C, Li Y, Louder M, Mascola J, Yang X, Sodroski J, Wyatt R. (2005). Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric: HIV-1 envelope glycoproteins. Virology. 331:33-46.
24. Gzyl J, Bolesta E, Wierzbicki A, Kmieciak D, Naito T, Honda M, Komuro K, Kaneko Y, Kozbor D. (2004). Effect of partial aad complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses. Virology. 318:493-506.
25. Haggerty S, Dempsey MP, Bukrinsky MI, Guo L, Stevenson M. (1991). Posttranslational modifications within the HIV-1 envelope glycoprotein which restrict virus assembly and CD4-dependent infection. AIDS Research an&Human Retreviruses. 7:501-10.
26. Haigwood NL, Nara PV, Brooks E, Nest GAV, Ott G, Higgins KW, Dunlop N. Scandella CJ, Eichberg JW, Steimer KS. (1992). Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. Journal of Virology. 66:172-182.
27. Haigwood NL, Shuster JR, Moore GK, Lee, H, Sidles PV, Higgins KW, Barr PJ, George-Nascimento C, Steimer KS. (1990). Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Research and Human Retroviruses 6:855-869.
28. Hansen JE, Clausen H, Hu SL, Nielsen JO, Olofsson S. (1992). An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus. Archives of Virology. 126:11-20.
29. Hansen JE, Clausen H, Nielsen C, Teglbjaerg LS, Hansen LL, Nielsen CM, Dabelsteen E, Mathiesen L, Hakomori SI, Nielsen JO. (1990). Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization. Journal of Virology. 64:2833-40.
30. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM. (2005). Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 308:1906-8.
31. Herrera C, Spenlehauer C, Fung MS, Burton DR, Beddows S, Moore JP. (2003). Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. Journal of Virology. 77:1084-91.
32. Jeffs SA, Shotton C, Balfe P, McKeating JA. (2002). Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. Journal of General Virology. 83:2723-32.
33. Johnson WE, Morgan J, Reitter J, Puffer BA, Czajak S, Doms RW, Desrosiers RC. (2002). A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. Journal of Virology. 76:2075-86.
34. Johnson WE, Sanford H, Schwall L, Burton DR, Parren PW, Robinson JE, Desrosiers RC. (2003). Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. Journal of Virology. 77:9993-10003.
35. Kang SM, Shi Quan F, Huang C, Guo L, Ye L, Yang C, Compans RW. (2005). Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology. 331:20-32.
36. Kim JH, Pitisuttithum P, Kamboonruang C, Chuenchitra T, Mascola J, Frankel SS, DeSouza MS, Polonis V, McLinden R, Sambor A, Brown AE, Phonrat B, Rungruengthanakit K, Duliege AM, Robb ML, McNeil J, Birx DL. (2003). Specific antibody responses to vaccination with bivalent CM235/ SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1. AIDS Research and Human Retroviruses. 19:807-16.
37. Kim YB, Han DP, Cao C, Cho MW. (2003). Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology. 305:124-37.
38. Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, Hendrickson WA, Sodroski J, Wyatt R. (2003). Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology. 313:387-400.
39. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J. (2001). Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. Journal of Virology. 75:3435-43.
40. Kolchinsky P, Kiprilov E, Sodroski J. (2001). Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. Journal of Virology. 75:2041-2050.
41. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. (1996). Quantitative analysis of serum neutralization of human immunodeficciency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. Journal of Virology. 70:445-458.
42. Law M, Cardoso RM, Wilson IA, Burton DR. (2007). Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. Journal of Virology. 81:4272-85.
43. Li B. Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, Allen S, Hunter E, Hahn BH, Shaw GM, Blackwell JL, Derdeyn CA. (2006). Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. Journal of Virology. 80:5211-8.
44. Li Y, Rey-Cuille MA, Hu SL. (2001). N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection. AIDS Research and Human Retroviruses. 17:1473-9.
45. Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, Wyatt R. (2006). Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. Journal of Virology. 80:1414-26.
46. Liang X, Munshi S, Shendure J, Mark G, 3rd, Davies ME, Freed DC, Montefiori DC, Shiver JW. (1999). Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine. 17:2862-72.
47. Lu S, Wyatt R, Richmond M, Mustafs, F, Wang S, Weng J, Montefiori DC, Sodroski J, Robinson HL. (1998). Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/V2 and V3 regions. AIDS Research and Human Retroviruses. 14:151-155.
48. Ly A, Stamatatos L. (2000). V2 loop Glycosylation of the human Immunodeficiency Virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. Journal of Virology. 74:6769-6776.
49. Malenbaum SE, Yang D, Cavacini L, Posner M, Robinson J, Cheng-Mayer C. (2000). The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. Journal of Virology. 74:11008-16.
50. Mathews TJ, Weinhold KJ, Lyarly HK, Langois AJ, Wigzell H, Bolognesi DP. (1987). Interaction between tne human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proceedings of the National Academy of Sciences. of the United States of America. 84:5424-5428.
51. McCaffrey RA, Saunders C, Hensel M, Stamatatos L. (2004). N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. Journal of Virology. 78:3279-95.
52. McElrath MJ, Corey L, Montefiori D, Wolff M, Schwartz D, Keefer M, Belshe R, Graham BS, Matthews T, Wright P, Gorse G, Dolin R, Berman P, Francis D, Duliege AM, Bolognesi D, Stablein D, Ketter N, Fast P. (2000). A phase II study of two HIV type I envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Research and Human Retroviruses. 16:907-19.
53. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. (1996). Inter-and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 serotypes. Journal of Virology. 70:427-444.
54. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, Corcoran P, Zwick MB, Frand M, Morris L, Roux KH, Burton DR, Binley JM. (2006). Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. Journal of Virology. 80:2515-28.
55. Mori K, Yasutomi Y, Ohgimoto S, Nakasone T, Takamura S, Shioda T, Nagai Y. (2001). Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain. Journal of Virology. 75:4023-8.
56. Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P, Polonis V, Benenson M, VanCott T, Ratto-Kim D, Kim J, Thapinta D, Garner R, Bussaratid V, Singharaj P, el-Habib R, Gurunathan S. Heyward W, Birx D, McNeil J, Brown AE. (2004). Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. Journal of Infectious Diseases. 190:702-6.
57. Pancera M, Wyatt R. (2005). Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology. 332:145-56.
58. Pantophlet R, Wilson IA, Burton DR, (2003). Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. Journal of Virology, 77:5889-901.
59. Pikora C, Wittish C, Desrosiers RC. (2005). Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4. Journal of Virology. 79:12575-83.
60. Poignard P, Moulard M, Golez E, Vivona V, Franti M, Venturini S, Wang M, Parren PW, Burton DR. (2003). Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. Journal of Virology. 77:353-65.
61. Quinones-Kochs MI, Buonocore L, Rose JK. (2002). Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. Journal of Virology. 76:4199-211.
62. Reitter JN, Desrosiers RC. (1998). Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein. Journal of Virology. 72:5399-5407.
63. Reitter JN, Means RE, Desrosiers RC. (1998). A role for carbohydrates in immune evasion in AIDS. Nature Medicine. 4:679-684.
64. Reynard F, Fatmi A, Verrier B, Bedin F. (2004). HIV-1 acute infection env glycomutants designed from 3D model: effects on processing, antigenicity, and neutralization sensitivity. Virology. 324:90-102.
65. Richardson JTM, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, Doms RW. (1996). Humoral response to oligomeric human immunodeficiency virus, type 1 envelope protein. Journal of Virology. 70:753-762.
66. Richman DD, Wrin T, Little SJ, Petropoulos CJ. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America. 100:4144-9.
67. Sanders RW, Venturi K Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP. (2002). The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. Journal of Virology. 76:7293-305.
68. Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Malenbaum SE, Burke B, Cheng-Mayer C, Stamatatos L. (2005). The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. Journal of Virology. 79:9069-80.
69. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. (2002). The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alphal->2 mannose residues on the outer face of gp120. Journal of Virology. 76:7306-21.
70. Schonning K, Jansson B, Olofsson S, Nielsen JO, Hansen JES. (1996). Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology. 218:134-140.
71. Schulke N, Vesanen MS, Sanders RW, Zhu P, Lit M, Anselma DJ, Villa AR, Parren PW, Binley JM, Roux KH, Maddon PJ, Moore JP, Olson WC. (2002). Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. Journal of Virology. 76:7760-76.
72. Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW, Burton DR. (2005). Comparing antigenicity and immunogenicity of engineered gp120. Journal of Virology. 79:12148-63.
73. Si Z, Phan N, Kiprilov E, Sodroski J. (2003). Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Research and Human Retroviruses. 19:217-26.
74. Srivastava IK, Stamatatos L, Yon E, Vajdy M, Lian Y, Hilt S, Martin L, Vita C, Zhu P, Roux KH, Vojtech L, D CM, Donnelly J, Ulmer JB, and Barnett SW. (2003). Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate. Journal of Virology. 77:11244-11259.
75. Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, Coates SR, Leung L, Wininger M, Donnelly JJ, Ulmer JB, Baraett SW. (2002). Purification and characterization of oligomeric envelope glycoprotein from a primary r5 subtype B human immunodeficiency virus. Journal of Virology. 76:2835-47.
76. Stamatatos L, Cheng-Mayer C. (1998). An envelope modification that renders a primary, neutralization resistant, clade B HIV-1 isolate highly susceptible to neutralization by sera from other clades. Journal of Virology. 72:7840-7845.
77. Sugiura W, Broder CC, Moss B, Earl PL. (1999). Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins. Virology. 254:257-267.
78. Trkola A, Purtscher K Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. (1996). Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Journal of Virology. 70:1100-8.
79. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. (1995). Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. Journal of Virology. 69:5723-5733.
80. Wyatt R, Sullivan N, Thali M, Repke H, Ho D, Robinson J, Posner M, Sodroski J. (1993). Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. Journal of Virology. 67:4557-4565.
81. Yang X, Wyatt R, Sodroski J. (2001). Improved Elicitation of Neutralizing Antibodies against Primary Human Immunodeficiency Viruses by Soluble Stabilized Envelope Glycoprotein Trimers. Journal of Virology. 75:1165-1171.
82. Yang ZY, Chakrabarti BK, Xu L, Welcher B, Kong WP, Leung K, Panet A, Mascola JR, Nabel GJ. (2004). Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. Journal of Virology. 78:4029-36.
83. Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE. (2006). Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. Journal of Virology. 80:3030-41.